Akari Therapeutics

1.46
0.01 (0.69%)
At close: Apr 24, 2025, 3:59 PM
1.46
0.00%
After-hours: Apr 24, 2025, 04:00 PM EDT
0.69%
Bid 1.46
Market Cap 21.08K
Revenue (ttm) n/a
Net Income (ttm) -19.52M
EPS (ttm) -2.58
PE Ratio (ttm) -0.57
Forward PE n/a
Analyst n/a
Ask 1.49
Volume 63,382
Avg. Volume (20D) 31,447
Open 1.45
Previous Close 1.45
Day's Range 1.44 - 1.49
52-Week Range 0.85 - 4.40
Beta 0.58

About AKTX

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous p...

Industry Biotechnology
Sector Healthcare
IPO Date Jan 6, 2014
Employees 8
Stock Exchange NASDAQ
Ticker Symbol AKTX
Full Company Profile
1 month ago
+20%
Akari Therapeutics shares are trading higher after... Unlock content with Pro Subscription